PSG-1 inhibited tumor growth and resulted in tumor apoptosis.
PSG-1 caused a marked increase in cAMP and PKA activities and the PKA protein level.
PSG-1 decreased cGMP, PKC activities, PKC protein expression and intracellular [Ca2+]i.
PSG-1 improved the immune system function in tumor-bearing mice.
PSG-1 has potential as a novel therapeutic agent for carcinoma patients.